Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients

Figure 2

Serum IL-5 and IFN-γ levels reflect clinical response to anti-PD-1 mAbs in metastatic GC patients. Serum IL-5 and IFN-γ levels were assessed at BL, BR, and PD. (a) The median IL-5 levels at BR were lower than that at BL in the effective group; (b) the median IFN-γ levels at BR were lower than that at BL in the effective group; (c) the median IL-5 and IFN-γ levels at PD were higher than that at BL in the ineffective group; (d) the median IL-5 and IFN-γ levels at PD were higher than that at BL in the ineffective group. Statistical difference between median IL-5 and IFN-γ levels in different time-points was made by nonparametric Wilcoxon matched-pairs ranked tests. , , .

(a)

(b)

(c)

(d)